Midweek Takeaway with Anthony Tennyson, CEO of Solvonis Therapeutics plc (LSE: SVNS) #SVNS

This week on the Midweek Takeaway, Phil Carroll and Kevin Hornsby are joined by Anthony Tennyson from Solvonis Therapeutics to discuss the company’s recent £1.3 million fundraise and how the new capital will support its three priority clinical programs.

The conversation covers the potential expansion of SVN 001 into Europe, progress towards Phase IIb readiness for SVN 002 in the US, ongoing work with the National Institute on Drug Abuse on SVN 015, and the key regulatory and clinical milestones investors should be watching over the coming months.

Disclaimer & Declaration of Interest

This podcast may contain paid promotions, including but not limited to sponsorships, endorsements, or affiliate partnerships. The information, investment views, and recommendations provided are for general informational purposes only and should not be construed as a solicitation to buy or sell any financial products related to the companies discussed. Any opinions or comments are made to the best of the knowledge and belief of the commentators; however, no responsibility is accepted for actions based on such opinions or comments. The commentators may or may not hold investments in the companies under discussion. Listeners are encouraged to perform their own research and consult with a licensed professional before making any financial decisions based on the content of this podcast.